Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 4Withdrawn 2Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

liposomal doxorubicin 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Doxorubicin 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Leukemia, Plasma Cell × Clear all
NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Thomas Jefferson University

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡